BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 28594920)

  • 1. Genetic polymorphisms associated with fatty liver disease and fibrosis in HIV positive patients receiving combined antiretroviral therapy (cART).
    Dold L; Luda C; Schwarze-Zander C; Boesecke C; Hansel C; Nischalke HD; Lutz P; Mohr R; Wasmuth JC; Strassburg CP; Trebicka J; Rockstroh JK; Spengler U
    PLoS One; 2017; 12(6):e0178685. PubMed ID: 28594920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between variants in or near PNPLA3, GCKR, and PPP1R3B with ultrasound-defined steatosis based on data from the third National Health and Nutrition Examination Survey.
    Hernaez R; McLean J; Lazo M; Brancati FL; Hirschhorn JN; Borecki IB; Harris TB; ; Nguyen T; Kamel IR; Bonekamp S; Eberhardt MS; Clark JM; Kao WH; Speliotes EK
    Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1183-1190.e2. PubMed ID: 23416328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic variants in GCKR and PNPLA3 confer susceptibility to nonalcoholic fatty liver disease in obese individuals.
    Lin YC; Chang PF; Chang MH; Ni YH
    Am J Clin Nutr; 2014 Apr; 99(4):869-74. PubMed ID: 24477042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between PNPLA3 (rs738409), LYPLAL1 (rs12137855), PPP1R3B (rs4240624), GCKR (rs780094), and elevated transaminase levels in overweight/obese Mexican adults.
    Flores YN; Velázquez-Cruz R; Ramírez P; Bañuelos M; Zhang ZF; Yee HF; Chang SC; Canizales-Quinteros S; Quiterio M; Cabrera-Alvarez G; Patiño N; Salmerón J
    Mol Biol Rep; 2016 Dec; 43(12):1359-1369. PubMed ID: 27752939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of European ancestry nonalcoholic fatty liver disease-associated variants in individuals of African and Hispanic descent.
    Palmer ND; Musani SK; Yerges-Armstrong LM; Feitosa MF; Bielak LF; Hernaez R; Kahali B; Carr JJ; Harris TB; Jhun MA; Kardia SL; Langefeld CD; Mosley TH; Norris JM; Smith AV; Taylor HA; Wagenknecht LE; Liu J; Borecki IB; Peyser PA; Speliotes EK
    Hepatology; 2013 Sep; 58(3):966-75. PubMed ID: 23564467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A genetic risk score is associated with hepatic triglyceride content and non-alcoholic steatohepatitis in Mexicans with morbid obesity.
    León-Mimila P; Vega-Badillo J; Gutiérrez-Vidal R; Villamil-Ramírez H; Villareal-Molina T; Larrieta-Carrasco E; López-Contreras BE; Kauffer LR; Maldonado-Pintado DG; Méndez-Sánchez N; Tovar AR; Hernández-Pando R; Velázquez-Cruz R; Campos-Pérez F; Aguilar-Salinas CA; Canizales-Quinteros S
    Exp Mol Pathol; 2015 Apr; 98(2):178-83. PubMed ID: 25597287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Polygenic Determinants of Non-Alcoholic Fatty Liver Disease (NAFLD) By a Candidate Genes Resequencing Strategy.
    Di Costanzo A; Belardinilli F; Bailetti D; Sponziello M; D'Erasmo L; Polimeni L; Baratta F; Pastori D; Ceci F; Montali A; Girelli G; De Masi B; Angeloni A; Giannini G; Del Ben M; Angelico F; Arca M
    Sci Rep; 2018 Feb; 8(1):3702. PubMed ID: 29487372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic variation at NCAN locus is associated with inflammation and fibrosis in non-alcoholic fatty liver disease in morbid obesity.
    Gorden A; Yang R; Yerges-Armstrong LM; Ryan KA; Speliotes E; Borecki IB; Harris TB; Chu X; Wood GC; Still CD; Shuldiner AR; Gerhard GS;
    Hum Hered; 2013; 75(1):34-43. PubMed ID: 23594525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic determinants of hepatic steatosis and serum cytokeratin-18 fragment levels in Taiwanese children.
    Lin YC; Chang PF; Chang MH; Ni YH
    Liver Int; 2018 Jul; 38(7):1300-1307. PubMed ID: 29314568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic determinants of steatosis and fibrosis progression in paediatric non-alcoholic fatty liver disease.
    Hudert CA; Selinski S; Rudolph B; Bläker H; Loddenkemper C; Thielhorn R; Berndt N; Golka K; Cadenas C; Reinders J; Henning S; Bufler P; Jansen PLM; Holzhütter HG; Meierhofer D; Hengstler JG; Wiegand S
    Liver Int; 2019 Mar; 39(3):540-556. PubMed ID: 30444569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of polymorphisms in GCKR and TRIB1 with nonalcoholic fatty liver disease and metabolic syndrome traits.
    Kitamoto A; Kitamoto T; Nakamura T; Ogawa Y; Yoneda M; Hyogo H; Ochi H; Mizusawa S; Ueno T; Nakao K; Sekine A; Chayama K; Nakajima A; Hotta K
    Endocr J; 2014; 61(7):683-9. PubMed ID: 24785259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Examining genetic associations with hepatic steatosis in Mexican-origin adults.
    Trejo MJ; Morrill KE; Klimentidis YC; Garcia DO
    Ann Hepatol; 2023; 28(5):101120. PubMed ID: 37271481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits.
    Speliotes EK; Yerges-Armstrong LM; Wu J; Hernaez R; Kim LJ; Palmer CD; Gudnason V; Eiriksdottir G; Garcia ME; Launer LJ; Nalls MA; Clark JM; Mitchell BD; Shuldiner AR; Butler JL; Tomas M; Hoffmann U; Hwang SJ; Massaro JM; O'Donnell CJ; Sahani DV; Salomaa V; Schadt EE; Schwartz SM; Siscovick DS; ; ; ; Voight BF; Carr JJ; Feitosa MF; Harris TB; Fox CS; Smith AV; Kao WH; Hirschhorn JN; Borecki IB;
    PLoS Genet; 2011 Mar; 7(3):e1001324. PubMed ID: 21423719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucokinase regulatory protein gene polymorphism affects liver fibrosis in non-alcoholic fatty liver disease.
    Petta S; Miele L; Bugianesi E; Cammà C; Rosso C; Boccia S; Cabibi D; Di Marco V; Grimaudo S; Grieco A; Pipitone RM; Marchesini G; Craxì A
    PLoS One; 2014; 9(2):e87523. PubMed ID: 24498332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NAFLD risk alleles in PNPLA3, TM6SF2, GCKR and LYPLAL1 show divergent metabolic effects.
    Sliz E; Sebert S; Würtz P; Kangas AJ; Soininen P; Lehtimäki T; Kähönen M; Viikari J; Männikkö M; Ala-Korpela M; Raitakari OT; Kettunen J
    Hum Mol Genet; 2018 Jun; 27(12):2214-2223. PubMed ID: 29648650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Noninvasive characterization of graft steatosis after liver transplantation.
    Karlas T; Kollmeier J; Böhm S; Müller J; Kovacs P; Tröltzsch M; Weimann A; Bartels M; Rosendahl J; Mössner J; Berg T; Keim V; Wiegand J
    Scand J Gastroenterol; 2015 Feb; 50(2):224-32. PubMed ID: 25429378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The rs738409 polymorphism of the PNPLA3 gene is associated with hepatic steatosis and fibrosis in Brazilian patients with chronic hepatitis C.
    Manchiero C; Nunes AKDS; Magri MC; Dantas BP; Mazza CC; Barone AA; Tengan FM
    BMC Infect Dis; 2017 Dec; 17(1):780. PubMed ID: 29258449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of PNPLA3 rs738409 variant (I148 M) on hepatic steatosis, necroinflammation, and fibrosis in Japanese patients with chronic hepatitis C.
    Yasui K; Kawaguchi T; Shima T; Mitsuyoshi H; Seki K; Sendo R; Mizuno M; Itoh Y; Matsuda F; Okanoue T
    J Gastroenterol; 2015 Aug; 50(8):887-93. PubMed ID: 25543233
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Basyte-Bacevice V; Skieceviciene J; Valantiene I; Sumskiene J; Petrenkiene V; Kondrackiene J; Petrauskas D; Lammert F; Kupcinskas J
    Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30875804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of chemotherapy-associated liver injury (CALI) in PNPLA3 p.148M allele carriers: Preliminary results of a transient elastography-based study.
    Casper M; Zimmermann S; Weber SN; Arslanow A; Lammert F; Krawczyk M
    Dig Liver Dis; 2020 Jan; 52(1):102-106. PubMed ID: 31669075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.